Reversible heart failure: The role of inflammatory activation

Postgraduate Medical Journal

Volumn 87, Issue 1024, 2011, Pages 110-115

  Robinson, Tim ^a   Smith, Alyson ^a   Channer, Kevin S ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOMYOPATHY; GENERAL CONDITION DETERIORATION; HEART FAILURE; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; INTENSIVE CARE; PREGNANCY; REVIEW; VIRUS INFECTION;

HEART FAILURE; HUMANS; INFLAMMATION; MYOCARDIAL INFARCTION;

EID: 79951545972     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.100123     Document Type: Review

References (54)

1. Lam CS, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail Published Online First: Aug 2010. doi:10.1093/eurjhf/hfq121.
2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
3. Chaggar P, Malkin CJ, Shaw SM, et al. Neuro-endocrine effects on the heart and targets for therapeutic manipulation in heart failure. Cardiovascular Therapeutics 2009;27:187-93.
4. Malkin C, Channer KS. Life-saving or life-prolonging? Interpreting trial data and survival curves for patients with congestive heart failure. European Journal of Heart Failure 2005;7:143-8. (Pubitemid 40215605)
5. Steeds RP, Channer KS. Heart failure; vive la difference. Heart 1997;78:537-8.
6. Lee SS, Joo YS, Kim WU, et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 2001;19:321-4.
7. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997;24:445-51. (Pubitemid 27153406)
8. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94. (Pubitemid 24115934)
9. Reilly PA, Cosh JA, Maddison PJ, et al. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis 1990;49:363-9. (Pubitemid 20170512)
10. Khan AH, Spodick DH. Rheumatoid heart disease. Semin Arthritis Rheum 1972;1:327-37.
11. Nicola PJ, Maradit-Kremers H, Roger VL, et al. The risk of congestive heart failure in rheumatoid arthritis; a population-based study over 46 years. Arthritis Rheum 2005;52:412-20. (Pubitemid 40216304)
12. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis; rates, predictors and the effect of anti-tumour necrosis factor therapy. Am J Med 2004;116:305-11. (Pubitemid 38230289)
13. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005;44:677-80. (Pubitemid 41487243)
14. Krishnagopalan S, Kumar A, Parrillo JE, et al. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002;8:376-88.
15. Vieillard-Baron A, Caille V, Charron C, et al. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008;36:1701-6.
16. Bouhemad B, Nicolas-Robin A, Arbelot C, et al. Isolated and reversible impairment of ventricular relaxation in patients with septic shock. Crit Care Med 2008;36:766-74.
17. Charpentier J, Luyt CE, Fulla Y, et al. Brain natiuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004:32:600-6.
18. King DA, Codish S, Novack V, et al. The role of cardiac troponin I as a prognosticator in critically ill medical patients: a prospective observational cohort study. Crit Care Med 2005;9:390-5.
19. Sutton MS, Cole P, Plappert M, et al. Effects of subsequent pregnancy on left ventricular function in peripartum cardiomyopathy. Am Heart J 1991;121:1776-8.
20. Ansari AA, Neckelmann N, Wang YC, et al. Immunologic dialogue between cardiac myocytes, endothelial cells, and mononuclear cells. Clin Immunol Immunopathol 1993;68:208-14. (Pubitemid 23278075)
21. Melvin KR, Richardson PJ, Olsen EG, et al. Peripartum cardiomyopathy due to myocarditis. N Eng J Med 1982;307:731-4. (Pubitemid 12056197)
22. Sliwa K, Skudicky D, Bergemann A, et al. Peripartum cardiomyopathy; analysis of clinical outcome, left ventricle function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000;35:701.
23. Bozkurt B, Villaneuva FS, Holubkov R, et al. Intravenous immunoglobuluin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999;34:177-80.
24. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007;128:589-600. (Pubitemid 46206082)
25. Moore J, Baldisseri MR. Amniotic fluid embolism. Crit Care Med 2005;33(10 Suppl):S279-85.
26. Fairbrother D, Frisanchio-Kiss S, Njoku DB, et al. Complement receptor 1& 2 deficincy increases coxsackie B3-induced myocarditis, dilated cardiomyopathy and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immun 2006;176:3516-24. (Pubitemid 43363999)
27. Alter P, Rupp H, Maisch B. Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy - relation to inflammation and cardiac function. Biochem Biophys Res Commun 2006;339:180-7. (Pubitemid 41697532)
28. Satoh M, Nakamura M, Akatsu T, et al. Expression of toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci (Lond) 2003;104:577-84. (Pubitemid 36713847)
29. Kim SM, Park JH, Chung SK, et al. Coxsackie virus B3 infection induces cyr61 activation via JNK to mediate cell death. J Virol 2004;78:13479-88.
30. Sole MJ, Liu PJ. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J Am Coll Cardiol 1993;22(4 Suppl A):99A-105A.
31. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe heart failure. N Engl J Med 1990;323:236-41. (Pubitemid 20225044)
32. Testa M, Yeh M, Lee P, et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J Am Coll Cardiol 1996;28:964-71. (Pubitemid 26348163)
33. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-6. (Pubitemid 26117714)
34. Ferrari R, Bachetti T, Confortini R, et al. Tumour necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
35. Tsutamoto T, Hisanaga T, Wada A, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of the heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-8. (Pubitemid 28153460)
36. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 1996;2:243-9.
37. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
38. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001;103:2055-9. (Pubitemid 32373007)
39. Kapadia S, Torre-Amione G, Yokoyama T, et al. Soluble TNF binding proteins modulate the negative inotropic properties of the TNF-alpha in vitro. Am J Physiol 1995;268:H517-25.
40. Bozkurt B, Kribbs SB, Clubb FJ Jr, et al. Pathophysiologically relevant concentrations of tumour necrosis factor-alpha promote progressive left ventricular dysfunction and remodelling in rats. Circulation 1998;97:1382-91. (Pubitemid 28182677)
41. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumour necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6. (Pubitemid 29293430)
42. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumour necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7. (Pubitemid 32200174)
43. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602. (Pubitemid 38451714)
44. Anker SD, Coats AJ. How to RECOVER from the RENAISSANCE? The significance of the results of the RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 2002;86:123-30. (Pubitemid 35284800)
45. Chung ES, Packer M, Lo KH, et al; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40.
46. Henriksen PA, Newby DE. Therapeutic inhibition of tumour necrosis factor alpha in patients with heart failure: cooling an inflamed heart. Heart 2003;89:14-18. (Pubitemid 36044281)
47. Parrillo JE, Cunnion RE, Epstein SE, et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989;321:1061-8. (Pubitemid 19256658)
48. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6. (Pubitemid 32097072)
49. Gullestad L, Aass H, Fjeld JG, et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001;103:220-5. (Pubitemid 32095406)
50. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998;101:890-8. (Pubitemid 28096086)
51. Voll RE, Roth EA, Girkontaite I, et al. Histone-specific Th0 AND Th1 clones derived from systemic lupus erythematosus patienrs induce double-stranded DNA antibody production. Arthritis Rheum 1997;40:2162-71. (Pubitemid 28016412)
52. Torre-Amione G, Sestier F, Radovancevic B, et al. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol 2004;44:1181-6. (Pubitemid 39208871)
53. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84. (Pubitemid 30207690)
54. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J 2008;29:2388-442.